Indaptus Therapeutics (INDP) Total Current Liabilities (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Total Current Liabilities of $932999.0 for Q1 2026, down 64.28% year-over-year from $2.6 million in Q1 2025, and down 84.85% quarter-over-quarter from $6.2 million in Q4 2025.
Indaptus Therapeutics (INDP) Total Current Liabilities (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $932999.0 for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 64.28% year-over-year to $932999.0; the TTM figure through Mar 2026 stood at $932999.0 (down 64.28% YoY), while the FY2025 annual figure was $6.2 million, up 81.46% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $932999.0, down from $6.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $8.5 million in Q2 2025, with the low at $932999.0 in Q1 2026.
- The 5-year median for Total Current Liabilities is $2.6 million (2025), against an average of $3.1 million.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities soared 341.51% in 2025, then sank 64.28% in 2026.
- Indaptus Therapeutics' Total Current Liabilities stood at $3.4 million in 2022, then fell by 19.2% to $2.8 million in 2023, then gained by 22.34% to $3.4 million in 2024, then surged by 81.46% to $6.2 million in 2025, then plunged by 84.85% to $932999.0 in 2026.
- Business Quant data shows INDP's Total Current Liabilities at $932999.0 in Q1 2026, $6.2 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 932,999.00 |
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 8.51 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | 1.82 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 2.88 Mn |
| Jun 30, 2022 | 3.62 Mn |
| Mar 31, 2022 | 3.68 Mn |
| Dec 31, 2021 | 4.60 Mn |
| Sep 30, 2021 | 5.78 Mn |
| Jun 30, 2021 | 5.44 Mn |